At a glance
ClinicalIndex Comparison Record- ✓Radiographically-confirmed progression or recurrence of primary or secondary Grade IV glioma (including infratentorial and subcortical)
- ✓Radiographically-confirmed progression or recurrence of primary or secondary Grade III astrocytoma
- ✓Failed previous radiation treatment or combined chemo-radiation
- ✓Age ≥18 years
- ✕Tumor size >30mm (length x width)
- ✕Multifocal tumor
- ✕Surgery within 7 days prior to informed consent
- ✕Anti-cancer therapy within 28 days prior to study drug
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT02704858Phase 2RecruitingMonitorUpdated 4mo ago · Completion was 3mo agoAn Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation
In Brief
A Phase 2 clinical trial evaluating Perillyl alcohol for Glioblastoma Multiforme. Currently recruiting, targeting 49 participants across 12 sites.
Signals
Detailed Summary
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase 1 is a standard cohort dose escalation 3+3 design used to determine the maximum tolerated dose for Phase 2a. There will be up to 24 patients enrolled in Phase 1. There will be 25 patients enrolled in Phase 2a. For both phases of the study, NEO100 will be self-administered four times daily for a 28-day treatment cycles until disease progression, death or patient withdraw from study for any reason, whichever occurs first. Version 10 of the protocol changed the inclusion criteria for Phase 2a to limit inclusion to those patients with progressive or recurrent primary or secondary Grade IV gliomas expressing IDH1 mutations. Prior to the protocol amendment, 4 patients were enrolled who were IDH1 wild-type. Therefore, an additional 28 patients will be recruited for a total of 32 patients enrolled into Phase 2a of this study to have 35 evaluable cases. Version 12 of the protocol expanded the inclusion criteria for Phase 2a to include those patients with progressive or recurrent Grade III Astrocytoma expressing IDH1 mutations. Review of the literature specific to these patients found the same expected time to progression and death. As a result, the number of patients to enroll remains 32 to have 35 evaluable cases.
Study Details
Timeline
Interventions
Intranasal administration